Skip to main content
SpringerLink
Log in

Adalimumab/infliximab/methotrexate

Lymphoproliferative disorder presenting as gamma heavy chain disease: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Tsunemine H, et al. Gamma heavy chain disease (gamma-HCD) as iatrogenic immunodeficiency- associated lymphoproliferative disorder: Possible emergent subtype of rheumatoid arthritis-associated gamma-HCD. Journal of Clinical and Experimental Hematopathology 59: 196-201, No. 4, 2019. Available from: URL: http://doi.org/10.3960/jslrt.19025

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adalimumab/infliximab/methotrexate. Reactions Weekly 1813, 15 (2020). https://doi.org/10.1007/s40278-020-80772-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-80772-0

Search

Navigation